HTSUY — Stock Film
STOCK FILMSCENE 1/10HTSUY · $2.94
Stock Expert AI presents
HTSUY
Hisamitsu Pharmaceutical Co., Inc
~3 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Hisamitsu Pharmaceutical Co., Inc. A quick introduction.

On the stock market since 2017, it operates in the world of health and science. It has 2,769 employees. Now — the numbers.

on the stock market since 2017
2,769 employees
$839M market value
Revenue last year:
$0
The net profit left over:
$0
Out of every $100 in sales, $12 stays as net profit.
THE SLICE THAT TURNS INTO PROFIT: 12%

This is an established company with proven profits.

THE SALES TREND
Sales are moving sideways.

No real growth.

$1.1B
2022
$957M
2023
$989.3M
2024
$1B
2025
$1.1B
2026
Cash on hand:
$0
Total debt:
$0
The cash outweighs the debt.

If every debt were paid off today, $744.7M would still be left in the vault — a solid cushion for hard times.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 3 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Fat profit per sale, but shrinking8/10
A strong cash pile8/10
WEAK SPOTS
The stock has lost its spark0/10
THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 71% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/2
Strong cash, light debt

There is $759.9M in the vault; even if every debt were paid off, $744.7M would remain.

2
THE BRIGHT SIDE · 2/2
Pays a steady dividend

It pays out $0.18 per share each year — regular cash for whoever holds the stock.

1
THE RISKS · 1/1
The stock has lost its spark

Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.

FINALE · THE GRADE
F
0 / 100 · MoonshotScore

On our five-subject report card, HTSUY sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: HTSUY is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 21, 2026 · stockexpertai.com · Stock Film